|
|
|
|
abarelix
A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists. Also called Plenaxis. (National Cancer Institute)
US Medicare To Cover Prostate Cancer Drug 17 Mar 2005
WASHINGTON MAR 16, 2005 (Reuters) - Medicare will pay for Praecis Pharmaceuticals Inc.'s prostate cancer drug abarelix (Plenaxis) for men with advanced disease ... Cancerpage.com,
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
<**results**>
Progress in Prostate Cancer: An Update Jul 4, 2004
A retrospective analysis of a study that compared abarelix with conventional ADT found that the median QT lengthened by 13 milliseconds with abarelix and 18 ... Medscape (subscription) -
PRAECIS PHARMACEUTICALS INCORPORATED Announces Plenaxis Has Been ... Jun 21, 2004
PRCS) today announced that The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent billing code for Plenaxis(R) (abarelix for injectable ... Business Wire (press release), CA -
PRAECIS PHARMACEUTICALS INCORPORATED To Present at the Needham & ... Jun 10, 2004
...needs. PRAECIS has received approval from the FDA to market Plenaxis(TM) (abarelix for injectable suspension) in the United States. ... Business Wire (press release), CA -
PRAECIS PHARMACEUTICALS INCORPORATED Receives FDA Clearance to ... Jun 22, 2004
...needs. PRAECIS has received approval from the FDA to market Plenaxis(R) (abarelix for injectable suspension) in the United States. ... Business Wire (press release), CA -
Resources from the National Cancer Institute on abarelix:
[an error occurred while processing this directive]
|
|
|
